Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a 15% revenue growth and improved gross margins, which are positive indicators. However, the continued net loss and increased operating expenses temper the optimism. The lack of strategic initiatives and operational updates, along with regulatory risks, further contribute to a neutral sentiment. Without additional insights from the Q&A and specific market cap information, the stock price is likely to remain relatively stable in the short term.
Key Financial Performance
Revenue Revenue for Q1 2026 was $12.5 million, representing a 15% increase year-over-year. This growth was driven by strong sales in Europe and the expansion of our distributor network.
Gross Margin Gross margin improved to 72% in Q1 2026, up from 68% in Q1 2025. The improvement was attributed to better manufacturing efficiencies and cost controls.
Operating Expenses Operating expenses were $10 million in Q1 2026, a 5% increase compared to Q1 2025. The increase was primarily due to higher R&D investments and marketing expenses.
Net Loss Net loss for Q1 2026 was $2 million, compared to a net loss of $3 million in Q1 2025. The reduction in net loss was due to higher revenue and improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks and uncertainties, which could lead to actual results differing from those discussed. This includes changes in market conditions that may impact projections.
Regulatory risks: The company is subject to regulatory risks as highlighted by the need to review risks discussed in their annual and quarterly reports filed with the SEC.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Cap Research
Chan CEO
Chief Medical
Co LLC
Conference reminder
Cytosorbents Conference
Deliargyris Chief
Director Efthymios
Division Kerr
Division PM
EDT afternoon
Efthymios Deliargyris
HC Wainwright
Jefferies LLC
LLC Research
Lee HC
Officer Phillip
Officer Sarcone
PM EDT
Peter Mariani
Phillip Chan
Research Division
Research Xun
Sarcone Jefferies
Wainwright Co
Xun Lee
Zacks Cap
conference Chief
gentleman Cytosorbents
reminder conference
CTSO Transcript
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a 15% revenue growth and improved gross margins, which are positive indicators. However, the continued net loss and increased operating expenses temper the optimism. The lack of strategic initiatives and operational updates, along with regulatory risks, further contribute to a neutral sentiment. Without additional insights from the Q&A and specific market cap information, the stock price is likely to remain relatively stable in the short term.
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
Unknown3-25
The earnings call presents mixed signals: improved financial metrics and gross margins are positive, but the increased operating loss and lack of specific guidance on FDA processes and German market improvements create uncertainty. The Q&A reveals cautious optimism but lacks concrete timelines and data. The absence of a new partnership or shareholder return plan further tempers any positive outlook. Therefore, the stock price is likely to remain stable in the short term.
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows positive growth in revenue and gross margin, but challenges like FDA delays, cash flow issues, and market competition create uncertainties. The Q&A session revealed management's optimism about margin improvement and sepsis treatment expansion but lacked clarity on German sales restructuring. Given these factors, the stock is likely to experience a neutral movement in the short term, as positive financial indicators are offset by regulatory and operational challenges.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there's positive growth in product sales and improved operating losses, the regulatory setbacks and lack of clear guidance on gross margins are concerning. The Q&A section reveals management's confidence in overcoming regulatory hurdles, but the lack of specificity and delays may worry investors. The stable gross margins and improved financial metrics are offset by increased operating expenses and regulatory uncertainties, resulting in a neutral sentiment. The absence of market cap information limits the prediction's precision.
CTSO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
